On the other hand, an inhibitor of PKC has been proposed as therapeutic option for psoriasis, based on its ability to reduce cytokine production in psoriatic patients [26], Our results suggest that targeting a PKC inhibitor more towards PKCθ and PKCα, and less towards PKCβ, might improve the efficacy of such a therapy (although PKCα has also been demonstrated to play a role in keratinocyte differentiation [27]). The gene discussed is PRRT2; the disease is psoriasis.